Sanofi, formerly known as Sanofi Aventis, is the manufaturer of the drug Calcort, the leading brand name form of the drug Deflazacort, a medicine which acts as an immuno-suppressive and anti-inflammatory. It functions in the body as a glucocorticoid, a type of corticosteroid which binds to the glucocorticoid receptor and play a key role in regulating immune system response, helping combat diseases caused by overactive immune systems.
Calcort is used for a variety of medical conditions including, to name a few, asthma, sarcoidosis, and crohn's disease. A review in 2017 found that it was approximately 70-90% as potent as prednisone, and that 7.5mg of it is equivalent in potency to 25mg of cortisone. and 20mg of hydrocortisone. The same review stated it has less side effects compared to prednisone on calcium metabolism and less risk of causing growth retardation in children or osteoporosis.
Calcort has been cited as a drug which can be used for men, women, and children suffering from a condition of the immune system that warrants its usage.
Calcort can be prescribed at a wide range of doses with the ultimate decision on dose and time of administration being one that is based on a medical practitioner's view. Always refer to product literature.